MarketPeel
Insider Trading Intelligence
Pricing
…
BC

Bernadette Connaughton

HALO
DIRECTOR · HALOZYME THERAPEUTICS, INC. · CIK 0001662521
FILING MIX · LIFETIME57%/43%
BUYS
17
SELLS
13
TOTAL VALUE
$1.12M
COMPANIES
2
ACTIVE SINCE
Apr 2020
HOLDINGS NOW
94,369
AVG SELL PX
$71.16
TRADE KIND
SHOWING 30 / 30
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
9 backtested trades · 8 horizons · 21 pending
Forward-return performance of every backtestable P/S trade by Bernadette Connaughton, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d9+33.33%-1.86%+0.86%-2.72%+0.63%—
14d9+44.44%-0.09%+0.89%-0.98%+0.34%—
30d9+77.78%-3.15%+2.32%-6.37%-6.77%—
60d9+66.67%-3.50%+3.03%-6.54%-10.90%—
90d9(1 pending)+75.00%-3.91%+2.85%-6.76%-12.44%—
180d9(2 pending)+100.00%-8.07%+3.16%-12.19%-11.96%—
1y9(9 pending)——————
2y9(9 pending)——————
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
HALO · 42,669 shares · as of Jul 1, 2026
012,73825,47638,21450,952202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 17 buys / 13 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
HALO
HALOZYME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,000$76.40$76.4K42,669Jul 1, 2026Jul 2, 2026 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
625$77.21$48.3K42,044Jul 1, 2026Jul 2, 2026 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
51,700——51,700Jun 17, 2026Jun 22, 2026 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,625$66.21$107.6K43,669Jun 1, 2026Jun 2, 2026 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
6,040——6,040May 5, 2026May 7, 2026 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
6,796——45,294May 5, 2026May 7, 2026 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,625$63.48$103.2K38,498May 1, 2026May 5, 2026 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,000$70.25$140.5K40,123Jan 5, 2026Jan 6, 2026 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
829$71.60$59.4K42,123Dec 1, 2025Dec 1, 2025 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,000$68.48$137.0K42,952Nov 10, 2025Nov 12, 2025 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,500$75.09$112.6K45,452Oct 1, 2025Oct 1, 2025 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
500$75.70$37.9K44,952Oct 1, 2025Oct 1, 2025 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
100$71.71$7.2K50,852Sep 2, 2025Sep 2, 2025 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
923$74.11$68.4K46,952Sep 2, 2025Sep 2, 2025 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,977$73.62$219.2K47,875Sep 2, 2025Sep 2, 2025 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
37,500——37,500Jun 6, 2025Jun 10, 2025 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,165——50,952May 1, 2025May 2, 2025 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,750——5,750May 1, 2025May 2, 2025 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
25,000——25,000May 30, 2024Jun 3, 2024 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
6,501——46,787Apr 25, 2024Apr 29, 2024 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
8,804——8,804Apr 25, 2024Apr 29, 2024 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
25,000——25,000Jun 1, 2023Jun 5, 2023 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
11,371——11,371May 5, 2023May 9, 2023 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
8,065——40,286May 5, 2023May 9, 2023 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALEGRANT
Gift
5,998——32,221Nov 16, 2022Nov 17, 2022 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
25,000——25,000Jun 9, 2022Jun 13, 2022 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
6,206——38,219May 5, 2022May 6, 2022 ↗View →
EDIT
EDITAS MEDICINE, INC.
PURCHASEGRANT
Stock grant
24,732——24,732Oct 26, 2021Oct 28, 2021 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,230——32,013May 5, 2021May 6, 2021 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
8,829——26,783Apr 30, 2020May 1, 2020 ↗View →
Other insiders · HALO
Loading peer insiders…
About this filer
CIK 0001662521
ROLE
Director
PRIMARY
HALO
COMPANIES
2
ACTIVE SINCE
Apr 2020
MARKETPEEL · /INSIDER/0001662521DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback